Details

Mexidol solution 50mg / ml, 2ml No. 20

acute disorders of cerebral circulation;

traumatic brain injury, the consequences of traumatic brain injury;

encephalopathy;

vegetative dystonia syndrome;

mild cognitive disorders of atherosclerotic genesis;

anxiety disorders in neurotic and neurosis-like states;

acute myocardial infarction (from the first day) as part of complex therapy;

primary open-angle glaucoma of various stages, as part of complex therapy;

relief of withdrawal symptoms in alcoholism with a predominance of neurosis-like and vegetative-vascular disorders;

acute intoxication with antipsychotic drugs;

acute purulent-inflammatory processes of the abdominal cavity (acute necrotizing pancreatitis, peritonitis) as part of complex therapy.

In / m or in / in (jet or drip).

When administered by infusion, the drug should be diluted in 0.9% sodium chloride solution.

Jet MexidolЃ is injected slowly over 5-7 minutes, drip - at a rate of 40-60 drops per minute. The maximum daily dose should not exceed 1200 mg.

In acute disorders of cerebral circulation, MexidolЃ is used in the first 10-14 days - intravenous drip of 200-500 mg 2-4 times a day, then 200-250 mg i / m 2-3 times a day for 2 weeks ...

For traumatic brain injury and the consequences of traumatic brain injury, MexidolЃ is used for 10-15 days intravenous drip of 200-500 mg 2-4 times a day.

In case of discirculatory encephalopathy in the decompensation phase, MexidolЃ should be administered intravenously in a stream or drip at a dose of 200-500 mg 1-2 times a day for 14 days. Then i / m at 100 - 250 mg / day for the next 2 weeks.

For the course prevention of discirculatory encephalopathy, the drug is administered intramuscularly at a dose of 200-250 mg 2 times a day for 10-14 days.

With mild cognitive impairment in elderly patients and with anxiety disorders, the drug is used in / m in a daily dose of 100 - 300 mg / day for 14 - 30 days.

In acute myocardial infarction, as part of complex therapy, MexidolЃ is administered intravenously or intramuscularly for 14 days, against the background of traditional therapy of myocardial infarction, including nitrates, beta-blockers, angiotensin-converting enzyme (ACE) inhibitors, thrombolytics, anticoagulant and antiplatelet agents, funds according to indications.
In the first 5 days, in order to achieve the maximum effect, the drug should be administered intravenously, in the next 9 days MexidolЃ can be administered intramuscularly.

Intravenous administration of the drug is carried out by drop infusion, slowly (to avoid side effects) in 0.9% sodium chloride solution or 5% dextrose (glucose) solution in a volume of 100Ц150 ml for 30Ц90 minutes.

If necessary, a slow jet injection of the drug is possible, lasting at least 5 minutes.

The introduction of the drug (intravenous or intramuscular) is carried out 3 times a day, every 8 hours. The daily therapeutic dose is 6-9 mg / kg of body weight per day, a single dose is 2-3 mg / kg of body weight. The maximum daily dose should not exceed 800 mg, single dose - 250 mg.

In case of open-angle glaucoma of various stages, as part of the complex therapy, MexidolЃ is administered intramuscularly at 100-300 mg / day, 1-3 times a day for 14 days.

In case of alcohol withdrawal syndrome, MexidolЃ is administered in a dose of 200-500 mg intravenously or intramuscularly 2-3 times a day for 5-7 days.

In case of acute intoxication with antipsychotic drugs, the drug is administered intravenously at a dose of 200-500 mg / day for 7-14 days.

In acute purulent-inflammatory processes of the abdominal cavity (acute necrotizing pancreatitis, peritonitis), the drug is prescribed on the first day both in the preoperative and postoperative periods. The doses administered depend on the form and severity of the disease, the prevalence of the process, and the options for the clinical course. The drug should be withdrawn gradually only after a stable positive clinical and laboratory effect.

In acute edematous (interstitial) pancreatitis, MexidolЃ is prescribed 200-500 mg 3 times a day, intravenously drip (in 0.9% sodium chloride solution) and intramuscularly.

Mild severity of necrotizing pancreatitis - 100-200 mg 3 times a day intravenously (in 0.9% sodium chloride solution) and intramuscularly.

Average severity - 200 mg 3 times a day intravenous drip (in 0.9% sodium chloride solution).

Severe course - at a pulse dosage of 800 mg on the first day with a double administration regimen; then 200-500 mg 2 times a day with a gradual decrease in the daily dose.

Extremely severe course - at an initial dosage of 800 mg / day until persistent relief of manifestations of pancreatogenic shock, after stabilization of the state, 300-500 mg 2 times a day intravenously (in 0.9% sodium chloride solution) with a gradual decrease in the daily dosage.

Active ingredient: ethylmethylhydroxypyridine succinate - 50 mg.

Excipients: sodium metabisulfite - 0.4 mg; water for injection up to 1 ml.

Acute violations of liver and kidney function,

increased individual sensitivity to the drug.

There have not been strictly controlled clinical studies of the safety of using MexidolЃ in children, during pregnancy and lactation.

Trade name of the drug:

MexidolЃ

Grouping name:

Ethylmethylhydroxypyridine succinate.

Chemical rational name:

2-ethyl-6-methyl-3-hydroxypyridine succinate.

Dosage form:

Solution for intravenous and intramuscular administration.

Composition:

Active ingredient: ethylmethylhydroxypyridine succinate - 50 mg.

Excipients: sodium metabisulfite - 0.4 mg; water for injection up to 1 ml.

Description:

Colorless or slightly yellowish transparent liquid in ampoules of 2 or 5 ml.

Pharmacotherapeutic group:

Antioxidant.
Means for correcting disorders in alcoholism, toxic and drug addiction.

Pharmacological properties:

Pharmacodynamics:
It has antihypoxic, membrane-protective, nootropic, anticonvulsant, anxiolytic effect, increases the body's resistance to stress. The drug increases the body's resistance to the effects of the main damaging factors, to oxygen-dependent pathological conditions (shock, hypoxia and ischemia, cerebrovascular accident, intoxication with alcohol and antipsychotic drugs (neuroleptics)).
MexidolЃ improves cerebral metabolism and blood supply to the brain, improves microcirculation and rheological properties of blood, and reduces platelet aggregation. It stabilizes the membrane structures of blood cells (erythrocytes and platelets) during hemolysis. It has a hypolipidemic effect, reduces total cholesterol and LDL cholesterol levels.
Reduces enzymatic toxemia and endogenous intoxication in acute pancreatitis.
The mechanism of action of Mexidol is due to its antihypoxant, antioxidant and membrane-protective action. It inhibits the processes of lipid peroxidation, increases the activity of superoxide dismutase, increases the lipid-protein ratio, reduces the viscosity of the membrane, and increases its fluidity. Modulates the activity of membrane-bound enzymes (calcium-independent phosphodiesterase, adenylate cyclase, acetylcholinesterase), receptor complexes (benzodiazepine, GABA, acetylcholine), which enhances their ability to bind to ligands, helps to maintain the structural and functional organization of biomembranes and transport of neuromembranes. MexidolЃ increases the content of dopamine in the brain.It causes an increase in the compensatory activity of aerobic glycolysis and a decrease in the degree of inhibition of oxidative processes in the Krebs cycle under conditions of hypoxia, with an increase in the content of ATP, creatine phosphate and activation of the energy-synthesizing functions of mitochondria, stabilization of cell membranes. MexidolЃ normalizes metabolic processes in the ischemic myocardium, reduces the zone of necrosis, restores and improves electrical activity and myocardial contractility, and also increases coronary blood flow in the ischemic zone, reduces the consequences of reperfusion syndrome in acute coronary insufficiency. Increases the antianginal activity of nitro drugs. MexidolЃ promotes the preservation of retinal ganglion cells and optic nerve fibers in progressive neuropathy caused by chronic ischemia and hypoxia.Improves the functional activity of the retina and optic nerve, increasing visual acuity.

Pharmacokinetics:
When administered intramuscularly, it is determined in blood plasma for 4 hours after administration. The time to reach the maximum concentration Tmax is 0.45Ц0.5 hours. Cmax with a dose of 400-500 mg is 3.5-4.0 ?g / ml. MexidolЃ quickly passes from the bloodstream to organs and tissues and is quickly eliminated from the body. The retention time of the drug (MRT) is 0.7-1.3 hours. The drug is excreted mainly in the urine, mainly in the glucuronoconjugated form and in small amounts unchanged.

Indications for use:

acute disorders of cerebral circulation;

traumatic brain injury, the consequences of traumatic brain injury;

encephalopathy;

vegetative dystonia syndrome;

mild cognitive disorders of atherosclerotic genesis;

anxiety disorders in neurotic and neurosis-like states;

acute myocardial infarction (from the first day) as part of complex therapy;

primary open-angle glaucoma of various stages, as part of complex therapy;

relief of withdrawal symptoms in alcoholism with a predominance of neurosis-like and vegetative-vascular disorders;

acute intoxication with antipsychotic drugs;

acute purulent-inflammatory processes of the abdominal cavity (acute necrotizing pancreatitis, peritonitis) as part of complex therapy.

Contraindications:

Acute violations of liver and kidney function,

increased individual sensitivity to the drug.

There have not been strictly controlled clinical studies of the safety of using MexidolЃ in children, during pregnancy and lactation.

Method of administration and dosage: